Group 1 - The core viewpoint of the articles highlights the positive impact of government policies on the pharmaceutical industry, particularly benefiting companies like Sanofi Pharmaceutical, which saw a stock increase of over 10% following the release of its annual performance report [1][2] - Sanofi Pharmaceutical reported a revenue of 9.108 billion yuan for the year ending December 31, 2024, representing a year-on-year increase of 16.5%, with a net profit attributable to shareholders of 2.09 billion yuan, up 34.9% [2] - The State Council issued an opinion aimed at enhancing the quality of traditional Chinese medicine (TCM) and promoting its high-quality development, outlining 21 key initiatives across eight areas [2] Group 2 - The investment outlook for the TCM sector in 2025 is optimistic, focusing on three main themes: state-owned enterprise reform, innovation in TCM drugs, and the introduction of a basic drug catalog [3] - The Hang Seng Medical ETF has seen significant growth, with an increase of 2.405 billion yuan in scale over the past six months, ranking in the top third among comparable funds [3] - The ETF's performance metrics include a maximum monthly return of 28.34% since inception and a year-to-date maximum drawdown of 6.06%, indicating strong performance relative to benchmarks [4] Group 3 - The Hang Seng Medical Healthcare Index currently has a price-to-earnings ratio (PE-TTM) of 24.39, which is below 99.64% of its historical values, suggesting it is undervalued [5] - The top ten weighted stocks in the Hang Seng Medical Healthcare Index account for 55.2% of the index, with notable companies including WuXi Biologics and BeiGene [5][6] - The ETF's management fee is 0.50%, and its tracking error is 0.032%, indicating high tracking precision compared to similar funds [4]

| 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | | --- | --- | | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | 股票發行人現金股息公告 | | | 發行人名稱 | 三生制药 | | 股份代號 | 01530 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2024年12月31日止年度之末期股息 | | 公告日期 | 2025年3月25日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | 財政年末 | 2024年12月31日 | | 宣派股息的報告期末 | 2024年12月31日 | | 宣派股息 | 每 股 0.25 HKD | | 股東批准日期 | 2025年6月25日 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | 每 股 0.25 HKD | | 匯率 | 1 HKD : 1 HKD | | 除淨日 ...

Financial Performance - Revenue increased by RMB 1,292.1 million or 16.5% to RMB 9,108.0 million[2] - Gross profit rose by RMB 1,186.8 million or 17.9% to RMB 7,828.4 million, with a gross margin of 86.0%[2] - Net profit attributable to equity holders increased by RMB 541.1 million or 34.9% to RMB 2,090.3 million[2] - Adjusted operating profit increased by RMB 366.4 million or 18.8% to RMB 2,318.8 million[2] - EBITDA rose by RMB 784.7 million or 32.8% to RMB 3,173.8 million[2] - Adjusted operating EBITDA increased by RMB 633.9 million or 22.9% to RMB 3,402.3 million[2] - Total comprehensive income for the year was RMB 2,217.5 million, compared to RMB 1,586.3 million in the previous year[4] - The company reported a net profit of RMB 2,217,549, an increase from RMB 1,586,292 in the previous year, representing a growth of approximately 39.8%[5] - Total comprehensive income for the year reached RMB 2,285,205, compared to RMB 1,484,965 in the prior year, indicating a year-over-year increase of about 53.8%[5] Assets and Liabilities - Non-current assets totaled RMB 14,865,806, up from RMB 14,432,345 in the previous year, reflecting an increase of approximately 3%[7] - Current assets increased to RMB 9,346,934 from RMB 9,192,683, marking a growth of about 1.7%[7] - The company's cash and cash equivalents stood at RMB 2,142,651, a decrease from RMB 2,611,161, indicating a decline of approximately 17.9%[7] - Trade receivables rose to RMB 1,305,160, compared to RMB 1,095,132 in the previous year, showing an increase of about 19.2%[7] - Current liabilities increased to RMB 5,463,524 from RMB 3,727,610, representing a significant rise of approximately 46.6%[7] - Non-current liabilities decreased from RMB 3,383,818 thousand in 2023 to RMB 712,886 thousand in 2024, a reduction of approximately 78.9%[8] - The net asset value increased from RMB 16,513,600 thousand in 2023 to RMB 18,036,330 thousand in 2024, representing a growth of about 9.2%[8] - The equity attributable to owners of the parent rose from RMB 14,033,771 thousand in 2023 to RMB 15,436,258 thousand in 2024, an increase of approximately 10%[8] Dividends and Shareholder Returns - The board proposed a final dividend of HKD 0.25 per share for the year ended December 31, 2024[2] - The group plans to distribute a final dividend of HKD 0.25 per share for the year ended December 31, 2023, amounting to RMB 545,302 thousand[38] Market and Product Development - The company plans to expand its market presence and invest in new product development to drive future growth[5] - The company introduced new products including Semaglutide injection and Paclitaxel oral solution in 2024, expanding its therapeutic areas[50] - The company maintained a market share of 66.6% in the platelet reduction treatment market in China for its core product, Tevaziv[50] - The company captured 42.0% of the total market share in the rhEPO market in China in 2024[50] Research and Development - The group has a robust R&D platform covering various innovative large and small molecule products, with a focus on antibody discovery and clinical trial management[76] - The group is advancing multiple innovative biopharmaceuticals and small molecule drugs, including SSS06 (NuPIAO) for anemia and CS1003 for advanced liver cancer[77] - The company completed the Phase III clinical trial for NuPIAO (SSS06) for treating anemia in chronic kidney disease patients in January 2024, achieving the primary endpoint[84] Financial Management - The total tax expense for the year was RMB 500,536 thousand, up from RMB 392,167 thousand in 2023, indicating an increase of approximately 27.7%[35] - The effective tax rate for the group for the year ended December 31, 2024, was 18.4%, down from 19.8% in 2023[36] - Total financing costs decreased to RMB 190,846 thousand in 2024 from RMB 212,296 thousand in 2023, reflecting a reduction of about 10.1%[30] Corporate Governance - The group is committed to maintaining high standards of corporate governance to protect shareholder interests and enhance corporate value[135] - The audit committee, consisting of three independent non-executive directors, has reviewed and approved the accounting principles and practices adopted by the group for the reporting period[140] Employee and Operational Costs - Employee benefits expenses totaled RMB 1,564,714 thousand in 2024, compared to RMB 1,362,262 thousand in 2023, marking an increase of about 14.8%[29] - Employee costs, including directors' remuneration (excluding any retirement benefit plan contributions), amounted to approximately RMB 1,469.8 million during the reporting period, compared to approximately RMB 1,271.5 million in the same period last year[131] Compliance and Reporting - The financial statements are prepared in accordance with International Financial Reporting Standards, ensuring compliance and transparency[10] - Ernst & Young has confirmed that the financial information in the preliminary results announcement is consistent with the group's consolidated financial statements[141]

Investment Rating - The report initiates coverage with a "Buy" rating for the company [4]. Core Views - The company is positioned as a leading player in the biopharmaceutical sector, with a strong portfolio of core products and an innovative pipeline that is expected to drive growth [1][13]. - The core products, including Tevaz (rhTPO) and Mandi (Minoxidil), dominate their respective markets, while the innovative pipeline, particularly SSGJ-707 (PD-1/VEGF dual antibody), shows promising clinical data and potential for international collaboration [2][4][14]. Summary by Sections Company Overview - Established in 1993, the company has over 100 national invention patents and more than 40 marketed products across various therapeutic areas, including nephrology, oncology, and autoimmune diseases [13][14]. - The company has a robust R&D infrastructure with four major research centers and a comprehensive CDMO platform [14]. Core Products and Market Position - Tevaz achieved sales of 2.48 billion CNY in H1 2024, capturing 66.2% of the Chinese market for thrombocytopenia treatment [14]. - Mandi holds over 70% market share in the hair loss treatment sector, with innovative product forms enhancing its competitive edge [3][14]. Innovative Pipeline - The innovative pipeline includes SSGJ-707, which has shown excellent clinical data in Phase II trials, and other promising candidates in autoimmune and oncology sectors [4][11]. - The company is actively pursuing international collaborations to expand its product offerings and market reach [2][4]. Financial Projections - The company is expected to see steady revenue growth, with projected revenues of 9.13 billion CNY in 2024 and 10.53 billion CNY in 2025, reflecting growth rates of 16.85% and 15.30% respectively [5]. - Net profit forecasts for 2024, 2025, and 2026 are 2.19 billion CNY, 2.46 billion CNY, and 2.77 billion CNY, indicating a strong recovery and growth trajectory [5][4].

Investment Rating - The report maintains an "Accumulate" rating for the pharmaceutical industry [7] Core Insights - The report emphasizes the leadership of Chinese companies in the PD-(L)1 bispecific antibody sector, highlighting it as a representative technology platform for new drug development in China [21][13] - The overall performance of the pharmaceutical sector has shown a 1.77% increase, outperforming both the ChiNext Index and the CSI 300 Index during the week of March 10-14 [13][14] Summary by Sections Recent Performance - The market experienced an upward trend with a notable surge on Friday, reflecting a shift from technology to non-technology sectors, particularly in consumer healthcare and policies related to the three-child policy [2][14] - The report notes that while innovative drugs and AI healthcare showed signs of correction, other themes such as consumer healthcare and small-cap innovations in Hong Kong gained traction [2][14] Future Outlook - In the short to medium term, the focus is on identifying opportunities in consumer healthcare, particularly those with attributes appealing to children and those positioned for consumption upgrades [15] - For 2025, the report anticipates improvements in the pharmaceutical payment sector due to supportive policies for commercial health insurance, indicating a gradual accumulation of positive changes [15] Strategic Allocation Thoughts - The report outlines two main strategies for investment: 1. **Pharmaceutical Style Rhythm**: Focus on consumer healthcare companies like Angelalign and Aier Eye Hospital, and innovative drug companies such as Innovent Biologics and BeiGene [16] 2. **Pharmaceutical Industry Logic**: Emphasizes the commercialization of innovative drugs and the integration of new technologies, with a focus on companies like CStone Pharmaceuticals and Zymeworks [17][19] Key Companies to Watch - The report suggests monitoring companies involved in PD-(L)1 bispecific antibodies, including CanSino Biologics, Innovent Biologics, and I-Mab Biopharma, as they are positioned at the forefront of clinical advancements [21][34]

Investment Rating - The report maintains an "Accumulate" rating for the company [6][8]. Core Insights - The company's main business is experiencing steady growth, which lays a solid foundation for performance. The core product, Teibiao, holds a 66% market share and has shown double-digit sales growth over the past two years. The company is expected to continue this growth trajectory through 2025-2026 [3][8]. - The clinical data for the PD-1/VEGF dual antibody SSGJ-707 is promising, showcasing its potential in various indications, including non-small cell lung cancer (NSCLC) and metastatic colorectal cancer (mCRC) [3][8]. Financial Summary - Revenue projections for 2024, 2025, and 2026 are estimated at 89.19 billion, 98.54 billion, and 110.40 billion RMB, respectively, reflecting growth rates of 14%, 10%, and 12% [7][8]. - Gross profit is expected to increase from 6,642 million RMB in 2023 to 9,494 million RMB by 2026, with net profit projected to rise from 1,549 million RMB in 2023 to 2,522 million RMB in 2026 [7][8]. Product Pipeline and Development - The company is actively expanding its product matrix through business development (BD) initiatives, introducing several promising products, which are expected to contribute to rapid revenue growth over the next three years [3][8]. - SSGJ-707 has shown an overall response rate (ORR) of 70% in 1L PD-L1 positive NSCLC and 81.3% in 1L squamous NSCLC, indicating its competitive edge in the market [9][10]. Market Position - The company is positioned favorably in the global PD-1/VEGF dual antibody development landscape, with SSGJ-707 currently in Phase II clinical trials and expected to complete further trials in 2025 [12][10].

三生制药（01530.HK） 证券研究报告/公司研究简报 2025 年 03 月 10 日 生物制品 | 买入（首次） 评级： | 公司盈利预测及估值 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | | 指标 | 2022A | 2023A | 2024E | 2025E | 2026E | | | 营业收入（百万元） | 6,869 | 7,836 | 8,916 | 9,890 | 11,052 | | 分析师：祝嘉琦 | 增长率 yoy% | 7% | 14% | 14% | 11% | 12% | | 执业证书编号：S0740519040001 | 归母净利润（百万元） | 1,915 | 1,549 | 2,044 | 2,280 | 2,562 | | Email：zhujq@zts.com.cn | 增长率 yoy% | 16% | -19% | 32% | 12% | 12% | | | 每股收益（元） | 0.80 | 0.65 | 0.85 | 0.95 | 1.07 | | 分析师：曹泽运 | 每股现金流量 | 0.91 ...

Investment Rating - The report assigns a "Buy" rating for the company, Sihuan Pharmaceutical (01530.HK), for the first time [1]. Core Insights - The company has a solid fundamental base and is entering a harvest period for innovative drugs, with significant revenue contributions from core products such as Teibiao, Erythropoietin, and Mandi, generating over 8 billion in revenue and over 2 billion in profit, corresponding to a 7x PE ratio. The company is expected to achieve a near 5-10% annual growth rate, supported by nearly 6 billion in cash assets for innovative drug R&D, with annual R&D investment around 1 billion, placing it among industry leaders [8]. - SSGJ-707 shows promising clinical data and has the potential to be a best-in-class VEGF/PD-1 dual antibody. It is currently advancing through four Phase II clinical studies, with significant anti-tumor activity and good safety profiles reported at the JPM conference. The domestic sales peak is estimated at around 4 billion, while overseas sales could reach 4.5 billion USD [8]. - The company has a rich pipeline in the autoimmune sector, with promising products like oral paclitaxel, which is expected to have a significant market potential due to its improved patient compliance compared to injectable forms [8]. - Existing core products are expected to grow steadily, with Teibiao and Erythropoietin leading the way in their respective markets, and Mandi solidifying its position as a leading treatment for androgenetic alopecia [8]. - The earnings forecast indicates a strong growth trajectory, with total revenue projected to reach 10.14 billion in 2025, and net profit expected to grow to 2.63 billion, reflecting a 9.55% increase [1]. Summary by Sections 1. Core Product Growth and Innovation Pipeline - The company has over 40 listed products across various fields, with a focus on blood, oncology, and autoimmune diseases. The pipeline includes 28 products under development, with SSGJ-707 showing promising Phase II clinical data [17][18]. 2. SSGJ-707: Differentiated Design and Synergistic Effects - SSGJ-707 is a dual-target VEGF/PD-1 antibody with significant potential, currently in four Phase II clinical studies. The drug has shown superior anti-tumor activity compared to competitors in early trials [35][52]. 3. Teibiao: Expanding Treatment Indications - Teibiao is a leading treatment for CIT, with ongoing efforts to expand its indications, which could enhance future growth opportunities [8]. 4. Erythropoietin: Market Leader with New Indications - The company holds a leading position in the erythropoietin market, with new indications being included in medical insurance, opening up a vast potential market [8]. 5. Mandi: Leading Product for Hair Loss - Mandi is positioned as a top product for androgenetic alopecia, filling a gap in the market for sensitive populations [8]. 6. Innovation: Rich Pipeline in Autoimmunity and Oral Paclitaxel Potential - The company has a diverse pipeline in the autoimmune sector, with oral paclitaxel expected to have significant market potential due to its ease of use and compliance advantages [8]. 7. Earnings Forecast and Valuation - The earnings forecast suggests a strong growth trajectory, with a target market value of approximately 40 billion, corresponding to a target price of around 17 HKD per share [8].

Investment Rating - The report assigns a "Buy" rating for the company, with a target price of approximately 17 HKD, indicating a potential market value of around 400 billion HKD [8]. Core Insights - The company has a solid fundamental base and is entering a harvest period for innovative drugs, with significant revenue contributions from core products such as Tevaz (特比澳), Erythropoietin (促红素), and Mandi (蔓迪), which collectively generate over 8 billion HKD in revenue and 2 billion HKD in profit [8]. - The SSGJ-707 drug shows promising clinical data and has the potential to be a best-in-class VEGF/PD-1 dual antibody, with peak domestic sales estimated at 4 billion HKD and potential overseas sales reaching 4.5 billion USD [8]. - The company has a robust pipeline in the autoimmune sector, with several promising candidates, including oral paclitaxel, which is expected to have significant market potential due to its improved patient compliance compared to injectable forms [8]. Summary by Sections 1. Core Product Growth and Innovation Pipeline - The company has over 40 marketed products and 28 in the pipeline, focusing on hematology, oncology, and autoimmune diseases, with SSGJ-707 showing particularly strong clinical results [17][18]. - The core products are driving steady revenue growth, with a reported revenue of 4.4 billion HKD in H1 2024, a year-on-year increase of 16.1% [21]. 2. SSGJ-707: Clinical Development and Market Potential - SSGJ-707 is advancing through multiple Phase II clinical trials, demonstrating significant anti-tumor activity and safety, with over 550 patients enrolled [35][53]. - The drug's peak sales potential is projected at 4 billion HKD domestically and 4.5 billion USD internationally, with expectations for substantial business development opportunities [8][35]. 3. Financial Projections and Valuation - The report forecasts a steady increase in total revenue from 7.869 billion HKD in 2023 to 10.137 billion HKD in 2025, with a corresponding rise in net profit from 1.549 billion HKD to 2.631 billion HKD [8]. - The company is valued at a P/E ratio of 7 times for 2024, significantly lower than its peers, indicating potential for price appreciation [8]. 4. Competitive Landscape and Market Position - The competitive landscape for PD-(L)1/VEGF dual antibodies is intensifying, with SSGJ-707 positioned favorably against other candidates like AK112, which has already shown promising results in clinical trials [36][38]. - The company’s innovative approach and strong pipeline are expected to enhance its market position and attract interest from global pharmaceutical companies [8][36].

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 的 全 部 或 任 何 部 分 內 容 所 產 生 或 因 倚 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：1530） 三生制药（「本公司」）董事會（「董事會」）謹 此 宣 佈，本 公 司 將 於 二 零 二 五 年 三 月 二十五日（星 期 二）舉 行 董 事 會 會 議，藉 以（其 中 包 括）審議及批准刊發本公司及其 附 屬 公 司 截 至 二 零 二 四 年 十 二 月 三 十 一 日 止 之 年 度 業 績 及 其 發 佈，並 考 慮 派 發 截至二零二四年十二月三十一日止年度之末期股息（如 有）。 承董事會命 三生制药 主 席 婁競博士 香 港，二 零 二 五 年 三 月 七 日 於 本 公 告 日 期，董 事 會 包 括 執 行 董 ...